NCT01264237

Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain

An Enriched Enrollment, Double-Blind, Placebo-Controlled, Parallel Group, Randomized Withdrawal Trial to Evaluate the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Moderate to Severe Neuropathic Pain

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Analgesic Solutions · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The present study will aim to determine the safety, efficacy, and tolerability of etoricoxib, an NSAID pain reliever, in patients with Neuropathic pain. Neuropathic pain, or pain caused by abnormal activity of sensory neurons, remains undertreated. Post herpetic neuralgia (PHN), which is commonly referred to as post-shingles pain, is the most useful disease to study when investigating the efficacy of pain relievers for Neuropathic pain. Therefore, this study will primarily involve patients with PHN. The hypothesis in this study is that etoricoxib efficacy is superior to that of placebo.

Conditions

• Postherpetic Neuralgia
• Neuralgia

Interventions

Type	Name	Description
DRUG	Etoricoxib	90mg Tablet QD at 10:00a.m.
DRUG	Placebo	One tablet QD at 10:00a.m.

Timeline

• Start date: 2011-03-01
• Primary completion: 2011-08-01
• Completion: 2012-04-01
• First posted: 2010-12-21
• Last updated: 2011-03-23

Locations

2 sites across 1 country: United Kingdom